2/27
12:00 pm
acrv
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]
Medium
Report
Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer [Yahoo! Finance]
2/24
08:33 am
acrv
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
Low
Report
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference [Yahoo! Finance]
2/24
08:00 am
acrv
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Neutral
Report
Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
2/23
08:00 am
acrv
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
Low
Report
Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress
2/21
02:04 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
2/18
08:00 am
acrv
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
Low
Report
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
1/28
09:15 am
acrv
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
Low
Report
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment
1/23
08:11 am
acrv
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
Low
Report
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
1/18
08:46 am
acrv
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
Low
Report
Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares [Yahoo! Finance]
1/10
01:07 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St
1/9
07:18 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
1/8
07:30 am
acrv
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
High
Report
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
1/6
07:30 am
acrv
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
High
Report
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
12/30
04:09 pm
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/23
04:09 pm
acrv
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/21
01:08 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
Medium
Report
Acrivon Therapeutics (NASDAQ:ACRV) was upgraded by analysts at
Wall Stre
12/17
09:34 am
acrv
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
Medium
Report
UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast
12/17
07:30 am
acrv
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
Medium
Report
Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates
12/13
01:10 am
acrv
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St
Low
Report
Acrivon Therapeutics (NASDAQ:ACRV) was downgraded by analysts at
Wall St
11/29
01:34 am
acrv
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT [Yahoo! Finance]
Low
Report
H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT [Yahoo! Finance]